Pharmacogenomic characterization of US FDA-approved cytotoxic drugs

Author： Peters Eric J   Motsinger-Reif Alison   Havener Tammy M   Everitt Lorraine   Hardison Nicholas E   Watson Venita G   Wagner Michael   Richards Kristy L   Province Mike A   McLeod Howard L  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.12, Iss.10, 2011-10, pp. : 1407-1415

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Public misconceptions about FDA-approved drugs

By  

Reactions Weekly, Vol. 1, Iss. 1372, 2011-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Identification of Novel Activators of Constitutive Androstane Receptor from FDA-Approved Drugs by Integrated Computational and Biological Approaches

By Lynch Caitlin  

Pharmaceutical Research, Vol. 30, Iss. 2, 2013-02 ,pp. : 489-501

Springer Publishing Company

Access to resources Recommend Favorite

FDA-approved Drugs Selected Using Virtual Screening Bind Specifically to G-quadruplex DNA

By  

Current Pharmaceutical Design, Vol. 19, Iss. 12, 2013-04 ,pp. : 2164-2173

Bentham Science Publishers

Access to resources Recommend Favorite

Consistency of drug–drug and gene–drug interaction information in US FDA-approved drug labels

By Conrado Daniela J   Rogers Hobart L   Zineh Issam   Pacanowski Michael A  

Pharmacogenomics, Vol. 14, Iss. 2, 2013-01 ,pp. : 215-223

Future Medicine

Access to resources Recommend Favorite

US FDA-Approved Disease-Modifying Treatments for Multiple Sclerosis: Review of Adverse Effect Profiles

By Steven L. Galetta   Clyde Markowitz  

CNS Drugs, Vol. 19, Iss. 3, 2005-01 ,pp. : 239-252

Adis International

Access to resources Recommend Favorite